Oxaliplatin-induced immune mediated thrombocytopenia
- First Online:
- Cite this article as:
- Beg, M.S., Komrokji, R.S., Ahmed, K. et al. Cancer Chemother Pharmacol (2008) 62: 925. doi:10.1007/s00280-007-0675-5
Oxaliplatin is a third generation platinum compound used in patients with advanced colorectal carcinoma. Recently, the mechanism of a rare drug-induced immune thrombocytopenia in patients receiving oxaliplatin has been described. This complication is caused by oxaliplatin-dependent antibodies directed against platelet surface glycoproteins, and is unrelated to myelosuppression. In this report, we describe two patients who developed thrombocytopenia immediately soon after receiving oxaliplatin. Sensitization presumably had occurred after receiving oxaliplatin during preceding courses of multiagent chemotherapy that included oxaliplatin.